Biopharmx Corp (BPMX) Given Daily News Impact Rating of 0.19
Media coverage about Biopharmx Corp (NYSE:BPMX) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biopharmx Corp earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.5336036443711 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Eye-Catching Hot Stocks: BioPharmX Corporation (NYSE: BPMX) – Alpha Beta Stock (alphabetastock.com)
- Today’s Hot Mover: BioPharmX Corporation (NYSE: BPMX) – Alpha Beta Stock (alphabetastock.com)
- Oversold Alert on BioPharmX Corporation (BPMX) – Wall Street Morning (wallstreetmorning.com)
- Signals from Technical Perspective: BioPharmX Corporation (NYSE: BPMX) – Alpha Beta Stock (alphabetastock.com)
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.